98%
921
2 minutes
20
BackgroundElectroencephalogram (EEG) is a promising, non-invasive method for identifying the presence of Alzheimer's disease (AD) by recognizing specific brain activity patterns associated with the disease. However, research on the correlation between EEG and the degree of cognitive impairment is still lacking.ObjectiveIn this study, we employ machine learning models to explore the potential of EEG in distinguishing different levels of cognitive impairment and various types of dementia.MethodsA total of 431 participants, including 77 cognitively unimpaired (CU), 167 patients with mild dementia, 110 patients with moderate dementia, and 77 patients with severe dementia were enrolled. Among them, 91 patients have detailed biomarker results to support differential diagnosis, with 77 AD and 14 frontotemporal dementia. After feature extraction, the rule-based representation learning was used to train models for EEG-based classification tasks.ResultsOur model can effectively differentiate between CU and moderate-to-severe dementia (AUC 0.8475), as well as between CU and AD patients in individuals under 65 (AUC 0.8170). However, our preliminary analysis was not able to effectively distinguish between different types of dementia. It is also challenging to differentiate between CU and mild dementia groups, as well as between the moderate and severe dementia.ConclusionsOur study suggests that EEG might be used not only in the early identification of AD, but also in the diagnosis and monitoring of the entire dementia spectrum, encompassing various stages and types of cognitive decline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/13872877251360331 | DOI Listing |
JAMA Netw Open
September 2025
School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
Importance: It is unclear whether the duration of amyloid-β (Aβ) pathology is associated with neurodegeneration and whether this depends on the presence of tau.
Objective: To examine the association of longitudinal atrophy with Aβ positron emission tomography (PET)-positivity (Aβ+) and the estimated duration of Aβ+ (Aβ+ duration), controlling for tau-positivity.
Design, Setting, And Participants: Data for this longitudinal cohort study were drawn from the Wisconsin Registry for Alzheimer Prevention and the Wisconsin Alzheimer Disease Research Center Clinical Core Study.
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Department of Pharmacology, Govt. College of Pharmacy, Rohru, Shimla, Himachal Pradesh, 171207, India.
Alzheimer's disease (AD) is the most common, complex, and untreatable form of dementia which is characterized by severe cognitive, motor, neuropsychiatric, and behavioural impairments. These symptoms severely reduce the quality of life for patients and impose a significant burden on caregivers. The existing therapies offer only symptomatic relief without addressing the underlying silent pathological progression.
View Article and Find Full Text PDFInquiry
September 2025
MED-EL-GmbH, Innsbruck, Austria.
Introduction: Age related hearing loss is in the top ten contributors to the global burden of disease and one of the largest modifiable risk factors for age-related dementia. However, awareness of the consequences of untreated hearing loss is poor and many adults do not seek hearing assessment. Despite World Health Organisation recommendations, no EU country currently has a national adult screening programme.
View Article and Find Full Text PDFBioelectromagnetics
September 2025
Competence Centre of Sleep Medicine, Charité -Universitaetsmedizin Berlin, Berlin, Germany.
A new whole-body exposure facility for a randomized, double-blind, cross-over provocation study investigating possible effects of 50 Hz magnetic field exposure on sleep and markers of Alzheimer's disease has been developed and dosimetrically analyzed. The exposure facility was custom-tailored for the sleep laboratory where the study was carried out and enables magnetic flux densities of up to 30 μT with a maximum field inhomogeneity of less than ± 20%. Exposure is applied fully software-controlled and in a blinded and randomized manner.
View Article and Find Full Text PDF